247 related articles for article (PubMed ID: 17845503)
1. Pharmacological modulation of gap junction function with the novel compound rotigaptide: a promising new principle for prevention of arrhythmias.
Kjølbye AL; Haugan K; Hennan JK; Petersen JS
Basic Clin Pharmacol Toxicol; 2007 Oct; 101(4):215-30. PubMed ID: 17845503
[TBL] [Abstract][Full Text] [Related]
2. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs.
Shiroshita-Takeshita A; Sakabe M; Haugan K; Hennan JK; Nattel S
Circulation; 2007 Jan; 115(3):310-8. PubMed ID: 17224477
[TBL] [Abstract][Full Text] [Related]
3. Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs.
Hennan JK; Swillo RE; Morgan GA; Keith JC; Schaub RG; Smith RP; Feldman HS; Haugan K; Kantrowitz J; Wang PJ; Abu-Qare A; Butera J; Larsen BD; Crandall DL
J Pharmacol Exp Ther; 2006 Apr; 317(1):236-43. PubMed ID: 16344331
[TBL] [Abstract][Full Text] [Related]
4. Treatment with the gap junction modifier rotigaptide (ZP123) reduces infarct size in rats with chronic myocardial infarction.
Haugan K; Marcussen N; Kjølbye AL; Nielsen MS; Hennan JK; Petersen JS
J Cardiovasc Pharmacol; 2006 Feb; 47(2):236-42. PubMed ID: 16495761
[TBL] [Abstract][Full Text] [Related]
5. Rotigaptide (ZP123) improves atrial conduction slowing in chronic volume overload-induced dilated atria.
Haugan K; Miyamoto T; Takeishi Y; Kubota I; Nakayama J; Shimojo H; Hirose M
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):71-9. PubMed ID: 16867174
[TBL] [Abstract][Full Text] [Related]
6. Rotigaptide (ZP123) reverts established atrial conduction velocity slowing.
Haugan K; Kjølbye AL; Hennan JK; Petersen JS
Cell Commun Adhes; 2005; 12(5-6):271-8. PubMed ID: 16531322
[TBL] [Abstract][Full Text] [Related]
7. Maintenance of intercellular coupling by the antiarrhythmic peptide rotigaptide suppresses arrhythmogenic discordant alternans.
Kjølbye AL; Dikshteyn M; Eloff BC; Deschênes I; Rosenbaum DS
Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H41-9. PubMed ID: 17982010
[TBL] [Abstract][Full Text] [Related]
8. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation.
Guerra JM; Everett TH; Lee KW; Wilson E; Olgin JE
Circulation; 2006 Jul; 114(2):110-8. PubMed ID: 16818812
[TBL] [Abstract][Full Text] [Related]
9. The antiarrhythmic peptide analog rotigaptide (ZP123) stimulates gap junction intercellular communication in human osteoblasts and prevents decrease in femoral trabecular bone strength in ovariectomized rats.
Jørgensen NR; Teilmann SC; Henriksen Z; Meier E; Hansen SS; Jensen JE; Sørensen OH; Petersen JS
Endocrinology; 2005 Nov; 146(11):4745-54. PubMed ID: 16109789
[TBL] [Abstract][Full Text] [Related]
10. The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model.
Rossman EI; Liu K; Morgan GA; Swillo RE; Krueger JA; Gardell SJ; Butera J; Gruver M; Kantrowitz J; Feldman HS; Petersen JS; Haugan K; Hennan JK
J Pharmacol Exp Ther; 2009 Jun; 329(3):1127-33. PubMed ID: 19252062
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of ventricular gap-junction coupling by rotigaptide.
Lin X; Zemlin C; Hennan JK; Petersen JS; Veenstra RD
Cardiovasc Res; 2008 Aug; 79(3):416-26. PubMed ID: 18430749
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction: evidence supporting a novel target for antiarrhythmic therapy.
Eloff BC; Gilat E; Wan X; Rosenbaum DS
Circulation; 2003 Dec; 108(25):3157-63. PubMed ID: 14656916
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents.
Piatnitski Chekler EL; Butera JA; Di L; Swillo RE; Morgan GA; Rossman EI; Huselton C; Larsen BD; Hennan JK
Bioorg Med Chem Lett; 2009 Aug; 19(16):4551-4. PubMed ID: 19616941
[TBL] [Abstract][Full Text] [Related]
14. Gap junction modifier rotigaptide decreases the susceptibility to ventricular arrhythmia by enhancing conduction velocity and suppressing discordant alternans during therapeutic hypothermia in isolated rabbit hearts.
Hsieh YC; Lin JC; Hung CY; Li CH; Lin SF; Yeh HI; Huang JL; Lo CP; Haugan K; Larsen BD; Wu TJ
Heart Rhythm; 2016 Jan; 13(1):251-61. PubMed ID: 26188250
[TBL] [Abstract][Full Text] [Related]
15. Effects of rotigaptide, a gap junction modifier, on defibrillation energy and resuscitation from cardiac arrest in rabbits.
Zhong JQ; Laurent G; So PP; Hu X; Hennan JK; Dorian P
J Cardiovasc Pharmacol Ther; 2007 Mar; 12(1):69-77. PubMed ID: 17495260
[TBL] [Abstract][Full Text] [Related]
16. Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation.
Butera JA; Larsen BD; Hennan JK; Kerns E; Di L; Alimardanov A; Swillo RE; Morgan GA; Liu K; Wang Q; Rossman EI; Unwalla R; McDonald L; Huselton C; Petersen JS
J Med Chem; 2009 Feb; 52(4):908-11. PubMed ID: 19175320
[TBL] [Abstract][Full Text] [Related]
17. Rotigaptide Infusion for the First 7 Days After Myocardial Infarction-Reperfusion Reduced Late Complexity of Myocardial Architecture of the Healing Border-Zone and Arrhythmia Inducibility.
Chowdhury RA; Debney MT; Protti A; Handa BS; Patel KHK; Lyon AR; Shah AM; Ng FS; Peters NS
J Am Heart Assoc; 2021 May; 10(9):e020006. PubMed ID: 33870715
[TBL] [Abstract][Full Text] [Related]
18. Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides.
Dhein S; Hagen A; Jozwiak J; Dietze A; Garbade J; Barten M; Kostelka M; Mohr FW
Naunyn Schmiedebergs Arch Pharmacol; 2010 Mar; 381(3):221-34. PubMed ID: 19943035
[TBL] [Abstract][Full Text] [Related]
19. Identification of ischemia-regulated phosphorylation sites in connexin43: A possible target for the antiarrhythmic peptide analogue rotigaptide (ZP123).
Axelsen LN; Stahlhut M; Mohammed S; Larsen BD; Nielsen MS; Holstein-Rathlou NH; Andersen S; Jensen ON; Hennan JK; Kjølbye AL
J Mol Cell Cardiol; 2006 Jun; 40(6):790-8. PubMed ID: 16678851
[TBL] [Abstract][Full Text] [Related]
20. The antiarrhythmic peptide rotigaptide (ZP123) increases connexin 43 protein expression in neonatal rat ventricular cardiomyocytes.
Stahlhut M; Petersen JS; Hennan JK; Ramirez MT
Cell Commun Adhes; 2006; 13(1-2):21-7. PubMed ID: 16613777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
